| Report ID | 278286 |
| Drug Identification Number | 00022780 |
| Brand name | DILANTIN |
| Common or Proper name | PHENYTOIN SODIUM |
| Company Name | BGP PHARMA ULC |
| Market Status | MARKETED |
| Active Ingredient(s) | PHENYTOIN SODIUM |
| Strength(s) | 100MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL ORAL |
| Packaging size | 1x100BTL CA, 1x1000 BTL CA |
| Anatomical Therapeutical Chemical (ATC) code | N03AB |
| Anatomical Therapeutical Chemical (ATC) description | ANTIEPILEPTICS |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | 2026-03-03 |
| Actual start date | |
| Estimated end date | 2026-04-14 |
| Actual end date | |
| Shortage status | Anticipated shortage |
| Updated date | 2026-02-24 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v6 | 2026-02-24 | French | Compare |
| v5 | 2026-02-24 | English | Compare |
| v4 | 2026-02-24 | French | Compare |
| v3 | 2026-02-24 | English | Compare |
| v2 | 2026-02-18 | French | Compare |
| v1 | 2026-02-18 | English | Compare |
Showing 1 to 6 of 6